^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR509-3 (MicroRNA 509-3)

    i
    Other names: MIR509-3, MicroRNA 509-3, Hsa-MiR-509-3-5p, Hsa-MiR-509-3p, Hsa-Mir-509-3, MIRN509-3, Hsa-Mir-506-P4b_pre, MIMAT0002881, MIMAT0004975, Mir-509-3, MI0005717, RF04216
    Associations

    News

    Trials
    3ms
    MiR-509-3p Targets YAP1 to Regulate Inflammatory Cytokines Against Hyperglycemia-Induced Renal Tubular Cell Damage in Diabetic Kidney Disease. (PubMed, Comb Chem High Throughput Screen)
    The study preliminarily suggests that miR-509-3p/YAP1 axis may act as a crucial regulator of hyperglycemia-induced tubular inflammation, offering a potential therapeutic target for DKD.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • YAP1 (Yes associated protein 1) • IL1B (Interleukin 1, beta) • MIR509-3 (MicroRNA 509-3)
    7ms
    Comprehensive Bioinformatic Analysis of Epithelial-Mesenchymal Transition (EMT) Network-Related microRNAs As Candidate Signatures in Prostate Adenocarcinoma. (PubMed, Cureus)
    The results of DIANA-plasmiR analysis showed that miR-34a-5p is a useful prognostic and diagnostic biomarker. Our results suggest that this study advances our knowledge of the molecular mechanism underlying prostate adenocarcinoma and that the interaction between the EMT gene and differentially expressed miR (DEmiR) in prostate adenocarcinoma may represent a target for prostate cancer diagnosis and treatment.
    Journal
    |
    CDH1 (Cadherin 1) • MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR34A (MicroRNA 34a-5p) • MIR429 (MicroRNA 429) • CDH2 (Cadherin 2) • MIR200A (MicroRNA 200a) • ITK (IL2 Inducible T Cell Kinase) • MIR141 (MicroRNA 141) • SNAI1 (Snail Family Transcriptional Repressor 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • MIR203A (MicroRNA 203a) • MIR509-3 (MicroRNA 509-3)
    over1year
    MiR-509-3p promotes gastric cancer development by activating FOXM1-mediated p38/MK2 pathway. (PubMed, Biomol Biomed)
    miR-509-3p inhibited GC by regulating FOXM1-mediated p38/MK2 pathway activation, and miR-509-3p mimics restrained tumor growth in vivo through this pathway. In conclusion, miR-509-3p suppresses GC malignant progression by regulating FOXM1-mediated p38/MK2 pathway activation.
    Journal
    |
    FOXM1 (Forkhead Box M1) • MIR509-3 (MicroRNA 509-3)
    |
    FOXM1 overexpression
    almost2years
    Helicobacter pylori infection induces gastric cancer cell malignancy by targeting HOXA-AS2/miR-509-3p/MMD2 axis. (PubMed, Genes Genomics)
    Hp infection induces the aggressiveness of GC cells by regulating HOXA-AS2/miR-509-3p/MMD2 axis.
    Journal
    |
    HOXA-AS2 (HOXA Cluster Antisense RNA 2) • MIR509-3 (MicroRNA 509-3)
    almost2years
    YB-1 Targeted by miR-509-3-5p Affects Migration and Invasion of Triple‑Negative Breast Cancer by Regulating Cellular Epithelial‑Mesenchymal Transition. (PubMed, Mol Biotechnol)
    In addition, miR-509-3-5p overexpression restrained TNBC tumor growth and downregulated the YB-1-mediated EMT process in vivo. YB-1 targeted by miR-509-3-5p affects motility of TNBC cells by regulating cellular EMT.
    Journal
    |
    YBX1 (Y-Box Binding Protein 1) • MIR509-3 (MicroRNA 509-3)
    over2years
    Study of MicroRNA Cluster Located on Chromosome X in Serum and Breast Cancer Tissue. (PubMed, Biochem Genet)
    The expression of all micro-RNAs in the tumor margin and BC tumor was significant with a P-value < 0.0001. Based on the ROC curves, all the mentioned microRNAs, except mir-888-5p, mir-513-a-5p, and mir-509-3p, exhibited high sensitivity and specificity and can be considered remarkable non-invasive tumor markers for breast cancer detection.
    Journal
    |
    MIR508 (MicroRNA 508) • MIR506 (MicroRNA 506) • MIR509-3 (MicroRNA 509-3) • MIR888 (MicroRNA 888)
    over2years
    The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells. (PubMed, J Ovarian Res)
    The miR-509-3p/DNMT1/SUMO-3 axis may be an ovarian cancer treatment target.
    Journal • Epigenetic controller
    |
    DNMT1 (DNA methyltransferase 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • MIR335 (MicroRNA 335) • COL11A1 (Collagen Type XI Alpha 1 Chain) • MIR509-3 (MicroRNA 509-3) • SUMO3 (Small Ubiquitin Like Modifier 3)
    |
    cisplatin
    over2years
    The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms. (PubMed, Front Immunol)
    FDA approved sorafenib combined with nivolumab (an inhibitor of PD-1/PD-L1) as the first line regimen for the treatment of advanced HCC. The present review highlights the current clinical applications and the molecular mechanisms of axitinib in advanced HCC. To move toward clinical applications by combining axitinib and other treatments in advanced HCC, more studies are still warranted in the near future.
    Review • Journal • Metastases
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • KDR (Kinase insert domain receptor) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • MIR509-3 (MicroRNA 509-3)
    |
    Opdivo (nivolumab) • sorafenib • axitinib
    almost3years
    Hsa_circ_0005273 acts as a sponge of miR-509-3p to promote the malignant behaviors of breast cancer by regulating HMMR expression. (PubMed, Thorac Cancer)
    Circ_0005273 knockdown might repress BC cell malignant behaviors by regulating the miR-509-3p/HMMR axis, which might provide a potential therapeutic target for BC.
    Journal
    |
    HMMR (Hyaluronan Mediated Motility Receptor) • MIR509-3 (MicroRNA 509-3)